Table 3.
Antimicrobial resistance profiles of CTX-M-producing Escherichia coli according to locations of acquisition and CTX-M types
|
Antimicrobial agent |
Total (n = 139) |
Hospital-onset (n = 60) |
Community-onset |
CTX-M type |
|
|
||
|---|---|---|---|---|---|---|---|---|
| Total (n = 79) | Healthcare-associated (n = 46) | Community-associated (n = 33) | CTX-M-14 (n = 69) | CTX-M-15 (n = 53) | CTX M-14 + M-15 (n = 17) | |||
| Amikacin |
14 (10.1) |
7 (11.7) |
7 (8.9) |
3 (6.5) |
4 (12.1) |
4 (5.8) |
7 (13.2) |
3 (17.6) |
| Gentamicin |
92 (65.5) |
45 (73.8) a |
47 (59.5) |
28 (60.9) |
19 (57.6) |
37 (53.6) |
40 (75.5)b |
15 (88.2)b |
| Tobramycin |
94 (67.6) |
46 (76.7) |
48 (60.8) |
29 (63.0) |
19 (57.6) |
36 (52.2) |
43 (81.1)b |
15 (88.2) b |
| Aztreonam |
130 (93.5) |
60 (100) |
70 (88.6) |
43 (93.5) |
27 (81.8) |
62 (89.9) |
51 (96.2) |
17 (100) |
| Cefepime |
132 (95.0) |
58 (96.7) |
74 (93.7) |
44 (95.7) |
30 (90.9) |
65 (94.2) |
51 (96.2) |
16 (94.1) |
| Ceftazidime |
77 (55.4) |
38 (63.9) |
39 (49.4) |
24 (52.2) |
15 (45.5) |
20 (29.0) |
43 (81.1)b |
14 (82.4) b |
| Cefotaxime |
139 (100) |
60 (100) |
78 (100) |
46 (100) |
32 (100) |
69 (100) |
52 (100) |
17 (100) |
| Ciprofloxacin |
105 (75.5) |
52 (86.7) a |
53 (67.1) |
34 (73.9) |
19 (57.6) |
47 (68.1) |
42 (79.2) |
16 (94.1)b |
| Piperacillin-tazobactam |
33 (23.7) |
20 (33.3) a |
13 (16.5) |
7 (15.2) |
6 (18.2) |
11 (15.9) |
10 (18.9) |
12 (70.6) b,c |
| Trimethoprim-sulfamethoxazole |
89 (64.0) |
38 (63.3) |
51 (64.6) |
29 (63.0) |
22 (66.7) |
52 (75.3) |
31 (58.5) b |
6 (35.3) b |
| Multidrug resistance |
120 (86.3) |
53 (88.4) |
67 (84.8) |
39 (84.8) |
28 (84.8) |
55 (79.7) |
48 (90.6) |
17 (100)b |
| Resistance scored ≥ 3 | 71 (51.1) | 39 (65.0) a | 32 (40.5) | 19 (41.3) | 13 (39.4) | 26 (37.7) | 31 (58.5) b | 14 (82.4) b |
a For comparison with CO isolates, P < 0.05.
b For comparison with CTX-M-14 producing isolates, P < 0.05.
c For comparison with CTX-M-15 producing isolates, P < 0.001.
d Number of antimicrobial classes, apart from penicillin and cephalosporin, to which E. coli isolates are non-susceptible.